Extravasation of topotecan, a report of two cases

Lonneke MM Oostweegel, MD, Laurence JC van Warmerdam, PhD, Margaret Schot, Ria C Dubbelman, Wim W Ten Bokkel Huinink, MD, Jos H Beijnen, PhD

Objective. Extravasations of anticancer agents may give serious complications and specific therapy might be needed. Topotecan is a new cytotoxic drug and is used in many clinical studies. In our clinic two extravasations of topotecan occurred, and the clinical consequences are discussed.

Clinical Features. The extravasations occurred in two patients who were receiving topotecan intravenously because of ovarian carcinoma stage III. The patients experienced some discomfort caused by the expansion of soft tissue, however, no serious complications were observed.

Case Progress and Outcome. Both patients received all further courses of topotecan without any negative effects.

Conclusion. In conclusion, besides stopping the injection, trying to aspirate the fluid, keeping the arm high, and cooling the swelling, we advise no specific measures to be taken after extravasation of topotecan.

Key Words: Topotecan; extravasation; adverse effects.

J Oncol Pharm Practice Vol 3, No 2, 1997 p115-116